DE10218974A1 - New (hetero)aryl-substituted carboxamide compounds, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or tumors - Google Patents

Abstract

(Hetero)aryl-carbamoyloxy- or (hetero)aryl-ureido-carboxylic acid N-substituted amide derivatives (I) are new. Carboxamides of formula (I) and their derivatives, solvates and stereoisomers (including mixtures in all proportions) are new. D = phenyl, pyridyl or thienyl (all optionally substituted by one or more of halo, A, OR2, N(R2)2, NO2, CN, COOR2 or CON(R2)2); X = NR3 or O; R1 = H, Ar, Het, cycloalkyl or A (optionally substituted by OR2, S(O)mR2, N(R2)2, Ar, Het, cycloalkyl, CN, COOR2 or CON(R2)2); R2 = H, A, -(C(R3)2)n-Ar, -(C(R3)2)n-Het, -(C(R3)2)n-cycloalkyl, -(C(R3)2)n-N(R3)2 or -(C(R3)2)n-OR3; R3 = H or A; W = -(C(R3)2)n-; Y = alkylene, cycloalkylene, Het-diyl or Ar-diyl; T = mono- or bicyclic saturated, unsaturated or aromatic carbocycle or heterocycle, containing 0-4 of N, O and/or S, substituted by 1-2 =S, =NR2, =NOR2, =NCOR2, =NCOOR2, =N-CN or =N-NO2 and optionally substituted by 1-3 halo, A, -(C(R3)2)n-Ar, -(C(R3)2)n-Het, -(C(R3)2)n-cycloalkyl, OR3, N(R3)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2NR2 and/or S(O)nA; A = 1-10C alkyl, optionally having 1 or 2 CH2 groups replaced by O, S and/or CH=CH and optionally substituted by 1-7 F; Ar = phenyl, naphthyl or biphenylyl (all optionally substituted by 1-3 halo, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, S(O)mA, -(C(R3)2)q-COOR21 or -O-(C(R3)2)q-COOR21); R21 = H, A, -(C(R3)2)n-Ar', -(C(R3)2)n-Het', -(C(R3)2)n-cycloalkyl, -(C(R3)2)n-N(R3)2 or -(C(R3)2)n-OR3; Ar' = phenyl or benzyl (both optionally substituted by 1-2 halo or A); Het = mono- or bicyclic saturated, unsaturated or aromatic heterocycle containing 1-4 N, O and/or S, optionally substituted by 1-3 =O, =S, =N(R3)2, halo, A, -(C(R3)2)n-Ar, -(C(R3)2)n-Het', -(C(R3)2)n-cycloalkyl, -(C(R3)2)n-OR21, -(C(R3)2)n-N(R21)2, NO2, CN, -(C(R3)2)n-COOR21, -(C(R3)2)n-CON(R21)2, -(C(R3)2)n-NR21COA, NR21CON(R21)2, -(C(R3)2)n-NR21SO2A, COR21, SO2NR21 and/or S(O)mA; Het' = mono- or bicyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N, O and/or S, optionally substituted by 1-2 =O, =S, =N(R3)2, halo, A, OR211, N(R211)2, NO2, CN, COOR211, CON(R211)2, -NR211COA, NR211CON(R211)2, NR211SO2A, COR211, SO2NR211 and/or S(O)mA; R211 = H, A, -(C(R3)2)n-Ar', -(C(R3)2)n-cycloalkyl, -(C(R3)2)n-N(R3)2 or -(C(R3)2)n-OR3; m, n = 0-2; and q = 1-3. An Independent claim is also included for the preparation of (I).

Description

The invention relates to compounds of the formula I.


wherein
D phenyl, pyridyl or thienyl which is unsubstituted or mono- or polysubstituted by Hal, A, OR ² , N (R ² ) ₂ , NO ₂ , CN, COOR ² or CON (R ² ) ₂ ,
X NR ³ or O,
R ¹ H, Ar, Het, cycloalkyl or
A, which may be substituted by OR ² , SR ² , N (R ² ) ₂ , Ar, Het, cycloalkyl, CN, COOR ² or CON (R ² ) ₂ ,
R ² H, A, - [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het, - [C (R ³ ) ₂ ] _n -cycloalkyl, - [C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
R ³ H or A,
W - [C (R ³ ) ₂ ] _n -,
Y alkylene, cycloalkylene, het-diyl or ar-diyl,
T is a mononuclear or dinuclear saturated, unsaturated or aromatic carbo- or heterocycle with 1 to 4 N, O and / or S atoms, which is mono- or doubly represented by = S, = NR ² , = NOR ² , = NCOR ² , = NCOOR ² , = NOCOR ² and is further substituted one, two or three times by Hal, A,
- [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het, - [C (R ³ ) ₂ ] _n -cycloalkyl, OR ³ , N (R ³ ) ₂ , NO _2, CN, COOR ^2, CON (R ²⁾ _2, NR ² COA, NR ² CON (R ²⁾ _2, NR ² SO ₂ A, COR ^2, SO ₂ NR ² and / or S (O) _m A substituted can be,
A unbranched or branched alkyl having 1-10 C atoms, wherein one or two CH ₂ groups by O or S atoms and / or by -CH = CH groups and / or 1-7 H atoms by F can be replaced
Ar unsubstituted or single, double or triple by Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ , CON (R ³ ) ₂ , NR ³ COA, NR ³ CON (R ³ ) ₂ , NR ³ SO ₂ A, COR ³ , SO ₂ N (R ³ ) ₂ , S (O) _m A, - [C (R ³ ) ₂ ] _n -COOR ^{2 '} or -O- [C (R ³ ) ₂ ] _o -COOR ^{2 '} substituted phenyl, naphthyl or biphenyl,
R ^{2 '} H, A, - [C (R ³ ) ₂ ] _n -Ar', - [C (R ³ ) ₂ ] _n -Het ', - [C (R ³ ) ₂ ] _n -cycloalkyl, - [ C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
R ^{2 ''} H, A, - [C (R ³ ) ₂ ] _n -Ar 'or - [C (R ³ ) ₂ ] _n -cycloalkyl, - [C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
Ar 'phenyl or benzyl which is unsubstituted or mono- or disubstituted by Hal or A,
Het is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, = S, = N (R ³ ) ₂ , Hal, A, - [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het ¹ , - [C (R ³ ) ₂ ] _n -cycloalkyl, - [C ( R ³ ) ₂ ] _n -OR ^{2 '} , - [C (R ³ ) ₂ ] _n -N (R ^2' ) ₂ , NO ₂ , CN, - [C (R ³ ) ₂ ] _n -COOR ^{2 '} , - [C (R ³ ) ₂ ] _n -CON (R ^{2 '} ) ₂ , - [C (R ³ ) ₂ ] _n -NR ^2' COA, NR ^{2 '} CON (R ^2' ) ₂ , - [C ( R ³ ) ₂ ] _n -NR ^{2 '} SO ₂ A, COR ^2' , SO ₂ NR ^{2 '} and / or S (O) _m A can be substituted,
Het ^{1 is} a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 2 N, O and / or S atoms, which is unsubstituted or mono- or disubstituted by carbonyl oxygen, = S, = N (R ³ ) ₂ , Hal, A, OR ^{2 "} , N (R ^2" ) ₂ , NO ₂ , CN, COOR ^{2 "} , CON (R ^2" ) ₂ , NR ^{2 "} COA, NR ^2" CON (R ^{2 ″} ) ₂ , NR ^{2 ″} SO ₂ A, COR ^{2 ″} , SO ₂ NR ^{2 ″} and / or S (O) _m A can be substituted,
Hal F, Cl, Br or I,
n 0, 1 or 2,
m 0, 1 or 2,
o 1, 2 or 3
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios.

The invention was based on the problem of new connections Find valuable properties, especially those that are used to manufacture of drugs can be used.

It has been found that the compounds of formula I and their salts good tolerance very valuable pharmacological properties have. In particular, they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic Diseases such as thrombosis, myocardial infarction, arteriosclerosis, Inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

The compounds of formula I according to the invention can also Inhibitors of coagulation factors factor VIIa, factor IXa and thrombin the blood coagulation cascade.

Aromatic amidine derivatives with antithrombotic activity are e.g. B. from EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO 00/71493, WO 00/71507, WO 00/71509, WO 00/71512, WO 00/71515 or WO 00/71516 known. Cyclic guanidines for treatment thromboembolic diseases are e.g. B. described in WO 97/08165. Aromatic heterocycles with factor Xa inhibitory activity are e.g. B. known from WO 96/10022. Substituted N - [(aminoiminomethyl) - phenylalkyl] azaheterocyclylamides as factor Xa inhibitors are in WO 96/40679 described.

The antithrombotic and anticoagulant effect of Compounds of the invention is based on the inhibitory effect against activated coagulation protease, known as factor Xa, or the inhibition of other activated serine proteases such as factor VIIa, Factor IXa or thrombin is attributed.

Factor Xa is one of the proteases involved in the complex process of Blood clotting is involved. Factor Xa catalyzes the conversion of Prothrombin in thrombin. Thrombin cleaves fibrinogen into fibrin monomers, which make a fundamental contribution to thrombus formation after cross-linking. A Activation of thrombin can lead to the occurrence of thromboembolic Lead diseases. An inhibition of thrombin can, however, in the Inhibit fibrin formation involved in thrombus formation.

The measurement of the inhibition of thrombin can e.g. B. according to the method by G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.

Inhibition of factor Xa can thus prevent thrombin is formed.

The compounds of formula I according to the invention and their salts intervene in the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.

The inhibition of factor Xa by the invention Compounds and the measurement of anticoagulant and antithrombotic activity can be determined according to the usual in vitro or in vivo Methods are determined. A suitable method is e.g. B. from J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223 described.

The measurement of the inhibition of factor Xa can e.g. B. according to the method by T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.

Coagulation factor VIIa initiates the after binding to tissue factor extrinsic part of the coagulation cascade and contributes to the activation of the Factor X to factor Xa. Inhibition of factor VIIa prevented thus the emergence of factor Xa and thus a subsequent one Thrombin formation.

The inhibition of factor VIIa by the invention Compounds and the measurement of anticoagulant and antithrombotic activity can be determined according to the usual in vitro or in vivo Methods are determined. A common method of measuring the Inhibition of factor VIIa is e.g. B. by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.

Coagulation factor IXa is in the intrinsic coagulation cascade generated and is also in the activation of factor X to factor Xa involved. Inhibition of factor IXa can therefore be done in other ways prevent factor Xa from being formed.

The inhibition of factor IXa by the invention Compounds and the measurement of anticoagulant and antithrombotic activity can be determined according to the usual in vitro or in vivo Methods are determined. A suitable method is e.g. B. from J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094 described.

The compounds of the invention can also be used for treatment of tumors, tumor diseases and / or tumor metastases become.

A relationship between the tissue factor TF / factor VIIa and the Development of various types of cancer was by T. Taniguchi and N.R. Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis of Pancreatic Cancer), 57-59.

The publications listed below describe an anti-tumor effect of TF-VII and factor Xa inhibitors in various types of tumor:
KM Donnelly et al. in thromb. Haemost. 1998; 79: 1041-1047;
EG Fischer et al. in J. Clin. Invest. 104: 1213-1221 (1999);
BM Mueller et al. in J. Clin. Invest. 101: 1372-1378 (1998);
ME Bromberg et al. in thromb. Haemost. 1999; 82: 88-92.

The compounds of formula I can be used as active pharmaceutical ingredients in the Human and veterinary medicine are used, especially for Treatment and prevention of thromboembolic disorders such as Thrombosis, myocardial infarction, arteriosclerosis, inflammation, Apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittent, venous thrombosis, pulmonary embolism, arterial Thrombosis, myocardial ischemia, unstable angina and on thrombosis based stroke.

The compounds of the invention are also used for treatment or Prophylaxis of atherosclerotic diseases such as coronary arterial Disease, cerebral arterial disease or peripheral arterial Disease used.

The compounds are also used in combination with other thrombolytics used for myocardial infarction, also for prophylaxis for Reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary artery bypass surgery.

The compounds of the invention are also used for Prevention of rethrombosis in microsurgery, further than Anticoagulants related to artificial organs or in the Hemodialysis.

The compounds are also used in the cleaning of Catheters and medical devices in patients in vivo, or as Anticoagulants for the preservation of blood, plasma and others Blood products in vitro. Find the compounds of the invention continue to be used in diseases in which the Blood coagulation contributes decisively to the course of the disease or one Represents source of secondary pathology, such as B. in cancer including metastasis, including inflammatory diseases Arthritis, as well as diabetes.

The compounds of the invention are also used for Treatment of migraines (F. Morales-Asin et al., Headache, 40, 2000, 45-47).

In the treatment of the diseases described, the Compounds according to the invention also in combination with others thrombolytically active compounds used, such as. B. with the "tissue plasminogen activator" t-PA, modified t-PA, streptokinase or urokinase. The compounds of the invention are with the other substances mentioned either simultaneously or before or given afterwards.

The simultaneous administration with aspirin is particularly preferred To prevent recurrence of thrombus formation.

The compounds of the invention are also used in Combination with platelet glycoprotein receptor (IIb / IIIa) - Antagonists that inhibit platelet aggregation.

• a) eine Verbindung der Formel II
  
  
  worin
  R¹, W, Y und T die in Anspruch 1 angegebene Bedeutung haben,
  mit einer Verbindung der Formel III
  
  D-N=C=O III
  
  worin
  D die in Anspruch 1 angegebene Bedeutung hat,
  umsetzt,
  oder
• b) eine Verbindung der Formel IV
  
  H₂N-W-Y-T IV
  
  worin W, Y und T die in Anspruch 1 angegebene Bedeutung haben,
  mit einer Verbindung der Formel V
  
  
  worin
  L Cl, Br, I oder eine freie oder reaktionsfähig funktionell abgewandelte OH-Gruppe bedeutet und
  R¹, X und D die in Anspruch 1 angegebenen Bedeutungen haben,
  umsetzt,
  oder
• c) und/oder daß man in einer Verbindung der Formel I einen Rest T in einen anderen Rest T umwandelt,

indem man beispielsweise

• a) eine Sulfanylverbindung in eine Iminoverbindung umwandelt,

und/oder
eine Base oder Säure der Formel I in eines ihrer Salze umwandelt. The invention relates to the compounds of formula I and their salts and a process for the preparation of compounds of formula I according to claims 1-16 and their pharmaceutically usable derivatives, solvates and stereoisomers, characterized in that

• a) a compound of formula II
  
  
  wherein
  R ¹ , W, Y and T have the meaning given in claim 1,
  with a compound of formula III
  
  DN = C = O III
  
  wherein
  D has the meaning given in claim 1,
  implements,
  or
• b) a compound of formula IV
  
  H ₂ NWYT IV
  
  wherein W, Y and T have the meaning given in claim 1,
  with a compound of formula V
  
  
  wherein
  L means Cl, Br, I or a free or reactively functionally modified OH group and
  R ¹ , X and D have the meanings given in claim 1,
  implements,
  or
• c) and / or that in a compound of the formula I a radical T is converted into another radical T,

for example by

• a) converts a sulfanyl compound into an imino compound,

and or
converts a base or acid of the formula I into one of its salts.

The invention also relates to the optically active forms (Stereoisomers), the enantiomers, the racemates, the diastereomers as well as the hydrates and solvates of these compounds. Under Solvate's Compounds become deposits of inert solvent molecules understood the connections that are due to their mutual Develop attraction. Solvates are e.g. B. mono- or dihydrates or Alcoholates.

Pharmaceutically usable derivatives are understood to mean e.g. B. the Salts of the compounds according to the invention as well as so-called Prodrug compounds.

Prodrug derivatives are understood with z. B. alkyl or acyl groups, Sugar or oligopeptides modified compounds of formula I, the in the organism quickly to the effective invention Connections are split.

This also includes biodegradable polymer derivatives Compounds according to the invention, as z. B. in Int. J. Pharm. 115, 61-67 (1995) is described.

The invention also relates to mixtures of the invention Compounds of formula I, e.g. B. Mixtures of two diastereomers z. B. in Ratio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. These are particularly preferably mixtures stereoisomeric compounds.

For all residues that occur several times, such as B. A, the meanings are independent of each other. Above and below, the radicals or parameters D, W, X, Y, T, R ^{1 have} the meanings given in the formula I, unless expressly stated otherwise.

A means alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. A is preferably methyl, furthermore Ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl preferably z. B. trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms. Atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.

Cycloalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl, Cyclohexyl or cycloheptyl.

Alkylene preferably means methylene, ethylene, propylene, butylene, Pentylene or hexylene, furthermore branched alkylene.

COR ² means z. B. CHO or -COA.

-COA (acyl) preferably means acetyl, propionyl, but also butyryl, Pentanoyl, hexanoyl or e.g. B. Benzoyl.

Hal is preferably F, Cl or Br, but also I.

Ar means z. B. phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert.- Butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) phenyl, o-, m- or p- (N-methylaminocarbonyl) phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p- (N, N-dimethylamino) -phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) phenyl, o-, m- or p- (N-ethylamino) phenyl, o-, m- or p- (N, N-diethylamino) phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p- (methylsulfonamido) phenyl, o-, m- or p- (methylsulfonyl) phenyl preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro, 2-amino-3-chloro, 2-amino-4- chloro, 2-amino-5-chloro or 2-amino-6-chlorophenyl, 2-nitro-4-N, N-dimethylamino- or 3-nitro-4-N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4- aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4- bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro 4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3- Chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Ar preferably means z. B. unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ² , SO ₂ A, COOR ² or CN substituted phenyl. Ar particularly preferably means z. B. unsubstituted or mono- or disubstituted by Hal, A, OA, SO ₂ A, SO ₂ NH ₂ , COOR ² or CN substituted phenyl, such as. B. phenyl, 2-methylsulfonylphenyl, 2-aminosulfonylphenyl, 2-, 3- or 4-chlorophenyl, 4-methylphenyl, 4-bromophenyl, 3-fluoro-4-methoxyphenyl, 4-trifluoromethoxyphenyl, 4-ethoxyphenyl, 2-methoxyphenyl, 3-cyanophenyl or 4-ethoxycarbonylphenyl.

Ar very particularly preferably denotes unsubstituted phenyl, 4- Chlorophenyl or 2-methylsulfonylphenyl.

Y is preferably Het-diyl or Ar-diyl, particularly preferably unsubstituted or simply substituted by A, Cl or F Phenylene, also pyridine-diyl, preferably pyridine-2,5-diyl or Piperidin-diyl.

Y means in particular unsubstituted or simply by methyl, Ethyl, propyl, Cl or F substituted 1,3- or 1,4-phenylene.

Het means z. B. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5- Oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5- Isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3- Thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6- Quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.

The heterocyclic radicals can also be partially or completely hydrogenated his.

Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3- Piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5- . 6-, 7- or 8- 3,4-dihydro-2H-benzo [1,4] oxazinyl, more preferably 2,3- Methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4- (difluoromethylenedioxy) phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3- (2-oxomethylenedioxy) phenyl or also 3,4- Dihydro-2H-1,5-benzodioxepin-6- or -7-yl, further preferred 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo-furanyl.

T preferably denotes a mononuclear saturated or unsaturated heterocycle with 1 to 2 N and / or O atoms, which is mono- or doubly represented by = S, = NR ² , = NOR ² , = NCOR ² , = NCOOR ² , = NOCOR ² is substituted, in particular by = S, = NR ² or = NOR ² .

T means in particular one or two times piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl substituted by = NR ² , = S or = NOR ² , 1,3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo [2.2.2] octan-2-yl.

T further particularly preferably means z. B. 2-imino-piperidin-1-yl, 2-imino-pyrrolidin-1-yl, 2-imino-1H-pyridin-1-yl, 3-imino-morpholin-4-yl, 4-imino-1H- pyridin-1-yl, 2,6-diimino-piperidinl-yl, 2-imino-piperazin-1-yl, 2,6-diimino-piperazin-1-yl, 2,5-diimino-pyrrolidin-1-yl, 2-imino-1,3-oxazolidin-3-yl, 3-imino-2H-pyridazin-2-yl, 2-imino-azepan-1-yl, 2-hydroxy-6-iminopiperazin-1-yl or 2- Methoxy-6-iminopiperazin-1-yl, 2-imino-piperidin-1-yl is very particularly preferred, and also the corresponding hydroxyimino, thioxo and = N- (CH ₂ ) _1-3 NA ' ₂ derivatives, where A 'is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

In a further embodiment, T is 2-imino-piperidin-1-yl, 2- Imino-pyrrolidin-1-yl, 2-hydroxy-imino-piperidin-1-yl, 2-hydroxy-iminopyrrolidin-1-yl, 2-methoxy-imino-piperidin-1-yl, 2-methoxy-imino-pyrrolidin 1-yl.

D means in particular z. B. unsubstituted or single or double by Hal, A, hydroxy, methoxy, ethoxy, hydroxycarbonyl, Methoxycarbonyl or ethoxycarbonyl substituted phenyl, or unsubstituted or simply substituted by Hal pyridyl or thienyl. D very particularly preferably denotes 4-chlorophenyl or 3-chloro-2- pyridyl.

R ¹ preferably means z. B. H, unsubstituted or simply substituted by Hal phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl. R ¹ very particularly preferably denotes phenyl or alkyl having 1-6 C atoms which is unsubstituted or simply substituted by Hal. In a further preferred embodiment, R ^{1 also} means Het ', where Het' is preferably a 5- or 6-membered heterocycle having one or two N, O or S atoms, e.g. B. 2-thienyl or 2-furyl.

R ² preferably means z. B. H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

n is preferably 0 or 1.

m is preferably 2.

Y preferably means z. B. unsubstituted or simply by alkyl substituted 1,4-phenylene.

W is preferably absent.

The compounds of formula I can have one or more chiral centers own and therefore occur in different stereoisomeric forms. Formula I encompasses all of these forms.

Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following partial formulas Ia to Ip, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
in Ia D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR ² or COOR ² , or unsubstituted or monosubstituted by Hal, pyridyl or thienyl;
in Ib R ^{2 is} H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
in Ic R ^{1 is} H, unsubstituted or simply substituted by Hal, phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl;
in Id X denotes NH or O;
in Ie W is (CH ₂ ) _n ;
in If Y means Ar-diyl or Het-diyl,
in Ig T a mononuclear or dinuclear saturated, unsaturated or aromatic carbo- or heterocycle with 1 to 2 N and / or O atoms, which is mono- or doubly represented by = S, = NR ² , = NOR ² , = NCOR ² , = NCOOR ² , = NOCOR ^{2 is} substituted and can furthermore be mono- or disubstituted by Hal or A,
and wherein, if D is present, a simple substitution by NH ₂ can additionally occur at D;
in Ih T is a mononuclear or dinuclear saturated or unsaturated heterocycle having 1 to 2 N and / or O atoms, which is mono- or disubstituted by = NR ² , = S or = NOR ² ;
in Ii T piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl substituted once or twice by = NR ² , = S or = NOR ² , 1,3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo [2.2.2] octan-2-yl;
in Ij T piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl substituted once or twice by = NR ^2b , = S or = NOR ^2b , 1,3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA ',
A 'is alkyl with 1, 2, 3, 4, 5 or 6 carbon atoms, where 1-7 H atoms can be replaced by F;
in Ik T one or two ^times substituted by = NR ^2b , = S or = NOR ^2b piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl , 1,3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' is methyl, ethyl, propyl, isopropyl or butyl;
in Il Ar is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO ₂ A, COOR ² , SO ₂ NH ₂ or CN;
in Im phenyl unsubstituted or simply substituted by Hal or unsubstituted or simply substituted by Hal pyridyl or thienyl,
R ¹ H, unsubstituted or monosubstituted phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl,
X NH or O,
W is missing,
Y ar-diyl, pyridine-diyl or piperidine-diyl,
Ar is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO ₂ A, COOR ² , SO ₂ NH ₂ or CN,
T simply by = NR ^2b , = S or = NOR ^2b substituted piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' is methyl, ethyl, propyl, isopropyl or butyl;
in D phenyl unsubstituted or simply substituted by Hal or unsubstituted or simply substituted by Hal pyridyl or thienyl,
R ¹ H, unsubstituted or monosubstituted phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl,
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply by = NR ^2b , = S or = NOR ^2b substituted piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' is methyl, ethyl, propyl, isopropyl or butyl;
phenyl or thienyl which is unsubstituted or simply substituted by Hal in Io D,
R ¹ H, unsubstituted or simply substituted by Hal, phenyl or alkyl having 1-6 C atoms,
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply by = NR ^2b , = S or = NOR ^2b substituted piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' is methyl, ethyl, propyl, isopropyl or butyl;
phenyl or thienyl which is unsubstituted or simply substituted by Hal in Ip D,
R ¹ H, phenyl which is unsubstituted or simply substituted by Hal, alkyl having 1-6 C atoms or Het '
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply by = NR ^2b , = S or = NOR ^2b substituted piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl,
Het '2-thienyl or 2-furyl, mean
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios.

The compounds of formula I and also the starting materials for their Incidentally, production is carried out according to methods known per se, as described in literature (e.g. in standard works such as Houben-Weyl, Methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, namely under reaction conditions for the mentioned implementations are known and suitable. You can also do that use of variants known per se, not mentioned here in more detail do.

If desired, the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but immediately further reacted to the compounds of formula I.

The starting compounds of the formulas II, III, IV and V are generally known. If they are new, they can, however, be known Methods are made.

All compounds of the following formula VI (with R = H or methyl; n = 3, 4 or 5) can be synthesized according to the following scheme.

For example synthesis of 1- (4-amino-2-methylphenyl) piperidine-2-thione:

Alternatively, synthesis:

Synthesis of the phenylpiperidine-thione building block without methyl group:

Compounds of formula I can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.

The reaction is usually carried out in an inert solvent Presence of an acid-binding agent, preferably an alkali or Alkaline earth metal hydroxides, carbonates or bicarbonates or one other salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, sodium, calcium or cesium. Also the Addition of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or an excess of the phenol component of the Formula II or the alkylation derivative of formula III can be favorable. The response time is between depending on the conditions used a few minutes and 14 days, the reaction temperature between about 0 ° and 150 °, usually between 20 ° and 130 °.

Suitable inert solvents are, for. B. hydrocarbons such as hexane, Petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as Trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, Tetrahydrofuran (THF) or dioxane; Glycol ether like Ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), Ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or Mixtures of the solvents mentioned.

Compounds of the formula I can furthermore preferably be obtained by compounds of formula IV with compounds of formula V implements.

The reaction is usually carried out in an inert solvent and under conditions as stated above.

In the compounds of formula V, L is preferably Cl, Br, I or a free or a reactive modified OH group such. B. a activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or Arylsulfonyloxy with 6-10 C atoms (preferably phenyl or p-tolylsulfonyloxy).

Such residues for activation of the carboxy group in typical Acylation reactions are in the literature (e.g. in the standard works like Houben-Weyl, methods of organic chemistry, Georg-Thieme- Verlag, Stuttgart;).

Activated esters are conveniently formed in situ, e.g. B. by addition from HOBt or N-hydroxysuccinimide.

The reaction is usually carried out in an inert solvent Presence of an acid-binding agent, preferably an organic one Base such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline or an excess of the carboxy component of formula V. Also the addition of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid Alkali or alkaline earth metals, preferably potassium, sodium, Calcium or cesium can be beneficial.

The response time is between depending on the conditions used a few minutes and 14 days, the reaction temperature between about -30 ° and 140 °, usually between -10 ° and 90 °, in particular between about 0 ° and about 70 °.

The above-mentioned are suitable as inert solvents.

Compounds of formula I can also be obtained by Compounds of formula I from one of their functional derivatives Treat with a solvolysing or hydrogenolysing agent sets you free.

Preferred starting materials for solvolysis or hydrogenolysis are those that otherwise correspond to formula I, but instead of an or corresponding to several free amino and / or hydroxy groups contain protected amino and / or hydroxy groups, preferably those that, instead of an H atom connected to an N atom, carry an amino protecting group, especially those that replace one HN group carry an R'-N group, where R 'is an amino protecting group means, and / or those instead of the H atom of a hydroxy group carry a hydroxy protecting group, e.g. B. those of the formula I correspond, but instead of a group -COOH a group -COOR '' wear, wherein R "is a hydroxy protecting group. Preferred starting materials are also the oxadiazole derivatives, which are in the corresponding amidino compounds can be transferred.

Several - identical or different - protected amino and / or hydroxyl groups present in the molecule of the starting material his. If the existing protecting groups are different from each other, they can be split off selectively in many cases.

The term "amino protecting group" is well known and refers to on groups that are suitable, an amino group before chemical Protect (block) implementations that are easily removable after the desired chemical reaction elsewhere in the Molecule has been carried out. Typical of such groups are especially unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protecting groups according to the desired Reaction (or reaction sequence) is removed, its type and size is in the the rest not critical; however, preference is given to those with 1-20, especially 1-8 carbon atoms. The term "acyl group" is related to to understand the present procedure in the broadest sense. He enclosed by aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acid-derived acyl groups and in particular alkoxycarbonyl, aryloxycarbonyl and especially Aralkoxycarbonyl groups. Examples of such acyl groups are Alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl like Methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ ("Carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl like Mtr. Preferred amino protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, Benzyl and Acetyl.

The term "hydroxy protecting group" is also well known and refers to groups that are suitable for a hydroxy group protect chemical reactions that are easily removable, after the desired chemical reaction elsewhere in the Molecule has been carried out. They are typical of such groups unsubstituted or substituted aryl, aralkyl or Acyl groups, also alkyl groups. The nature and size of the Hydroxy protecting groups are not critical as they are chemical-based Reaction or sequence of reactions are removed again; are preferred Groups with 1-20, especially 1-10 carbon atoms. examples for Hydroxy protecting groups are u. a. Benzyl, 4-methoxybenzyl, p-nitrobenzoyl, p- Toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl are particularly preferred.

The liberation of the compounds of formula I from their Functional derivatives succeed - depending on the protective group used - e.g. B. with strong acids, suitably with TFA or perchloric acid, but also with other strong inorganic acids such as hydrochloric acid or Sulfuric acid, strong organic carboxylic acids such as trichloroacetic acid or Sulfonic acids such as benzene or p-toluenesulfonic acid. The presence an additional inert solvent is possible, but not always required. Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as Tetrahydrofuran or dioxane, amides such as DMF, halogenated Hydrocarbons such as dichloromethane, and also alcohols such as methanol, Ethanol or isopropanol, as well as water. Mixtures of aforementioned solvents in question. TFA is preferably used in Excess used without the addition of another solvent, Perchloric acid in the form of a mixture of acetic acid and 70% Perchloric acid in a ratio of 9: 1. The reaction temperatures for the cleavage are expediently between about 0 and about 50 °, preferably working one between 15 and 30 ° (room temperature).

The groups BOC, OBut and Mtr can e.g. B. preferred with TFA in Cleave dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 ° be the FMOC group with an approximately 5 to 50% solution of Dimethylamine, diethylamine or piperidine in DMF at 15-30 °.

Hydrogenolytically removable protective groups (e.g. CBZ, benzyl or the Release of the amidino group from its oxadiazole derivative)) can, for. B. by treatment with hydrogen in the presence of a catalyst (e.g. a noble metal catalyst such as palladium, advantageously on a support like coal) can be split off. The solvents are suitable specified above, in particular z. B. alcohols such as methanol or Ethanol or amides such as DMF. Hydrogenolysis is usually done with Temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar. A Hydrogenolysis of the CBZ group succeeds e.g. B. good at 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) Pd / C in methanol / DMF at 20-30 °.

Suitable inert solvents are, for. B. hydrocarbons such as hexane, Petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as Trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, Trifluoromethylbenzene, chloroform or dichloromethane; Alcohols like Methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (Methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, Dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.

Esters can e.g. B. with acetic acid or with NaOH or KOH in water, Water-THF or water-dioxane at temperatures between 0 and 100 ° be saponified.

Furthermore, free amino groups can be acylated in the usual way with an acid chloride or anhydride or alkylated with an unsubstituted or substituted alkyl halide, or reacted with CH ₃ -C (= NH) -OEt, advantageously in an inert solvent such as dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and + 30 °.

A base of formula I can with an acid in the associated Acid addition salt are transferred, for example by reaction equivalent amounts of base and acid in an inert solvent such as ethanol and subsequent evaporation. For this implementation In particular acids are considered, the physiologically harmless Deliver salts. So inorganic acids can be used, e.g. B. Sulfuric acid, nitric acid, hydrohalic acids such as Hydrochloric acid or hydrobromic acid, phosphoric acids such as Orthophosphoric acid, sulfamic acid, also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. B. Formic acid, acetic acid, propionic acid, pivalic acid, diethyl acetic acid, Malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, Lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, Ascorbic acid, nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid, Ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p- Toluenesulfonic acid, naphthalene mono- and disulfonic acids, Lauryl sulfuric acid. Salts with physiologically unacceptable acids, e.g. B. picrates, can be used to isolate and / or purify the compounds of the Formula I can be used.

On the other hand, compounds of the formula I with bases (e.g. sodium or potassium hydroxide or carbonate) in the corresponding metal, in particular alkali metal or alkaline earth metal, or in the corresponding Ammonium salts are converted.

Also physiologically acceptable organic bases, such as. B. Ethanolamine can be used.

Compounds of the formula I according to the invention can, owing to their Molecular structure can be chiral and can accordingly in different enantiomeric forms occur. You can therefore in racemic or in optically active form.

Since the pharmaceutical effectiveness of the Racemate or Can distinguish stereoisomers of the compounds according to the invention, it may be desirable to use the enantiomers. In these In some cases, the end product or the intermediate products may already be in enantiomeric compounds, by chemical known to those skilled in the art or physical measures, separated or already as such the synthesis can be used.

In the case of racemic amines, the mixture is reacted formed with an optically active release agent diastereomers. As Release agents are suitable for. B. optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, Malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the different optically active camphorsulfonic acids. One is also advantageous chromatographic separation of enantiomers using an optically active Release agents (e.g. dinitrobenzoylphenylglycine, cellulose triacetate or others Derivatives of carbohydrates or chiral derivatized ones fixed on silica gel Methacrylate). Aqueous or alcoholic solvent mixtures such as B. Hexane / isopropanol / acetonitrile e.g. B. in a ratio of 82: 15: 3.

The invention further relates to the use of the compounds of formula I and / or their physiologically acceptable salts for Manufacture of a medicament (pharmaceutical preparation), in particular in a non-chemical way. You can do this together with at least one solid, liquid and / or semi-liquid carrier or Excipient and optionally in combination with one or more other active ingredients are brought into a suitable dosage form.

The invention further relates to medicaments containing at least a compound of formula I and / or its pharmaceutically usable Derivatives, solvates and stereoisomers, including their mixtures in all ratios, as well as, if necessary, carriers and / or auxiliary substances.

These preparations can be used as medicinal products in human or Veterinary medicine can be used. Organic or inorganic substances in question that are suitable for enteral (e.g. oral), parenteral or topical application and with the new Compounds do not react, e.g. water, vegetable oils, Benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, pills, coated tablets, Capsules, powder, granules, syrups, juices or drops, for rectal Application suppositories, for parenteral application solutions, preferably oily or aqueous solutions, further suspensions, emulsions or implants, for topical application of ointments, creams or powder or as a nasal spray. The new connections can too lyophilized and the resulting lyophilizates z. B. for the production of Injectables are used. The specified preparations can be sterilized and / or auxiliary substances such as lubricants, preservatives, Stabilizing and / or wetting agents, emulsifiers, salts for Influencing the osmotic pressure, buffer substances, color, Contain flavor and / or several other active ingredients, e.g. B. a or more vitamins.

The compounds of formula I and their physiologically acceptable Salts can help fight and prevent thromboembolic disorders such as thrombosis, myocardial infarction, Arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraines, tumors, Tumor diseases and / or tumor metastases can be used.

The substances according to the invention are generally used preferably in doses between about 1 and 500 mg, in particular between 5 and 100 mg per dosage unit. The daily Dosage is preferably between about 0.02 and 10 mg / kg Body weight. However, the specific dose for each patient depends on the various factors, for example the effectiveness of special connection used, age, body weight, general state of health, gender, on food, on Administration time and route, from the excretion rate, Drug combination and severity of the disease, which the therapy applies. Oral application is preferred.

The invention further relates to medicaments containing at least a compound of formula I and / or its pharmaceutically usable Derivatives, solvates and stereoisomers, including their mixtures in all ratios, and at least one other drug ingredient.

• a) einer wirksamen Menge an einer Verbindung der Formel I und/oder ihrer pharmazeutisch verwendbaren Derivate, Solvate und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und
• b) einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs.

The invention also relates to a set (kit) consisting of separate packs of

• a) an effective amount of a compound of formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and
• b) an effective amount of another active pharmaceutical ingredient.

The set contains suitable containers, such as boxes or cartons, individual bottles, bags or ampoules. The set can e.g. B. contain separate ampoules, each containing an effective amount of a compound of formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios,
and an effective amount of another drug ingredient is dissolved or in lyophilized form.

The invention furthermore relates to the use of compounds of the formula I and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios,
for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases,
in combination with at least one other active pharmaceutical ingredient.

All temperatures above and below are given in ° C. In the The following examples mean "customary work-up": if required to add water, if necessary, depending on the constitution of the End product to pH values between 2 and 10, extracted with Ethyl acetate or dichloromethane, separates, dries the organic phase over sodium sulfate, evaporated and purified by chromatography Silica gel and / or by crystallization. Rf values on silica gel; Eluent: Ethyl acetate / methanol 9: 1.

Mass spectrometry (MS):
EI (electron impact ionization) M ⁺
FAB (Fast Atom Bombardment) (M + H) ⁺
ESI (Electrospray Ionization) (M + H) ⁺ (unless otherwise stated).

example 1 Production of amine building blocks a)

15 g (78.8 mmol) of 1- (4-aminophenyl) piperidin-2-one are taken together with 16.0 g (39.5 mmol) 2,4-bis- (4-methoxyphenyl) - [1,3,2,4] dithiadiphosphetane 2,4-disulfide (Lawesson's reagent) in 100 ml of anhydrous toluene Boiling heated. After 45 min. the solvent is evaporated and the Residue taken up in dichloromethane and 2 N HCl. The watery Phase is extracted three times with dichloromethane and with conc. NaOH on set a pH of 12. Extraction with dichloromethane, drying supply over sodium sulfate and evaporate the solvent 1- (4-aminophenyl) piperidine-2-thione as a colorless solid, ESI 207.

A solution of 3.74 g (18.1 mmol) of 1- (4-aminophenyl) piperidine-2-thione in 30 ml of acetone, 1.25 ml (20.0 mmol) of iodomethane are added and 48 Stirred for hours at room temperature. The reaction mixture is evaporated: 1- (4-aminophenyl) -6-methylsulfanyl-2,3,4,5-tetrahydropyridinium iodide as a brownish solid; ESI 221.

A solution of 2.68 g (12.1 mmol) of 1- (4-aminophenyl) -6-methylsulfanyl-2,3,4,5-tetrahydropyridinium iodide and 1.01 g (12.1 mmol) of O-methylhydroxylammonium chloride in 30 ml of ethanol is added 3.5 ml (25 mmol) of triethylamine were added and the mixture was stirred at room temperature for 20 hours. The reaction mixture is evaporated, taken up in water and the precipitate formed is filtered off: 1- (4-aminophenyl) piperidin-2-one-O-methyloxime as a colorless solid; ESI 220. b)

A mixture of 40.0 g (290 mmol) 4-nitroaniline and 40.0 ml (421 mmol) 4-Chlorobutyronitrile is boiled for 30 minutes using a hot air gun (approx. 190 ° C) heated. The mixture is allowed to cool and digested with it Ethyl acetate: 1- (4-nitro-phenyl) pyrrolidin-2-ylidenamine, hydrochloride as brown solid, ESI 206.

A solution of 25.0 g (103 mmol) 1- (4-nitro-phenyl) -pyrrolidin-2- ylidenamine, hydrochloride in 500 ml of methanol is mixed with 2.5 g water-moist palladium on activated carbon (5% Pd) and added for 17 hours Room temperature hydrogenated. The catalyst is filtered off and the filtrate evaporated: 1- (4-aminophenyl) pyrrolidin-2-ylidenamine, hydrochloride as brownish solid; ESI 176.

• 1. 1.1 Eine Lösung von 10.0 g (65.7 mmol) (R)-Mandelsäure und 10.0 g (65.1 mmol) 4-Chlorphenylisocyanat in 100 ml Dichlormethan wird mit 400 mg (0.63 mmol) Dibutylzinndilaurat versetzt und 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird auf Wasser gegeben und mit Ethylacetat extrahiert. Die organische Phase wird eingedampft: (R)-(4- Chlorphenylcarbamoyloxy)-phenylessigsäure als farbloser Feststoff; ESI 306
• 2. 1.2 Eine Lösung von 183 mg (0.600 mmol) (R)-(4-Chlorphenylcarbamoyloxy)-phenylessigsäure, 129 mg (0.588 mmol) 1-(4-Aminophenyl)-piperidin-2-on-O-methyl-oxim, 192 mg (1.00 mmol) N-(3- Dimethylaminopropyl)-N'-ethylcarbodiimidhydrochlorid (DAPECI) und 91.9 mg 0.600 mmol) Hydroxybenztriazolhydrat (HOBt) in 1 ml DMF wird mit 101 mg (1.00 mmol) 4-Methylmorpholin versetzt und 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird auf gesättigte Natriumhydrogencarbonatlösung gegeben und der entstandene Niederschlag abfiltriert. Der Niederschlag wird an einer Kieselgelsäule mit Petrolether/Ethylacetat als Laufmittel chromatographiert: (R)-2-[N-(4- Chlorphenyl)-carbamoyloxy]-N-[4-(2-methoxyimino-piperidin-1-yl)-phenyl]- 2-phenyl-acetamid ("AA") als farbloser Feststoff; ESI 507.
• 3. 1.3 Eine Lösung von 50 mg (0.099 mmol) (R)-(4-Chlorphenyl)- carbaminsäure-[4-(2-methoxyimino-piperidin-1-yl)-phenylcarbamoyl]- phenyl-methylester in 10 ml Methanol wird mit 0.3 g wasserfeuchtem Raney-Nickel versetzt und hydriert. Das Reaktionsgemisch wird filtriert und das Filtrat eingedampft. Der Rückstand wird an einer Kieselgelsäule mit Dichlormethan/Methanol als Laufmittel chromatographiert: (R)-2-[N-(4- Chlorphenyl)-carbamoyloxy]-N-[4-(2-imino-piperidin-1-yl)-phenyl]-2-phenylacetamid als farbloser Feststoff; ESI 477.
• 4. 1.4 30 mg (0.063 mmol) (R)-(4-Chlorphenyl)-carbaminsäure-[4-(2- imino-piperidin-1-yl)-phenylcarbamoyl]-phenylmethyl-ester werden in 0.063 ml 1 N HCl gelöst und lyophilisiert: (R)-2-[N-(4-Chlorphenyl)-carbamoyloxy]- N-[4-(2-imino-piperidin-1-yl)-phenyl]-2-phenyl-acetamid, Hydrochlorid ("AB") als farbloser Feststoff; ESI 477.

A solution of 2.68 g (12.7 mmol) of 1- (4-aminophenyl) pyrrolidin-2-ylidenamine, hydrochloride is dissolved in 70 ml of methanol, with 9.49 g (113 mmol) of sodium hydrogen carbonate and 4.06 g (48.6 mmol) of methoxylamine, Hydrochloride added and heated to 70 ° C for 48 hours. The reaction mixture is evaporated and the residue is taken up in acetone. The insoluble constituents are filtered off and the filtrate is evaporated. The residue is chromatographed on a silica gel column using ethyl acetate as the eluent: 1- (4-aminophenyl) pyrrolidin-2-one-O-methyl-oxime as a brownish solid; ESI 206. Preparation of 2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-iminopiperidin-1-yl) phenyl] -2-phenyl-acetamide

• 1. 1.1 A solution of 10.0 g (65.7 mmol) of (R) -mandelic acid and 10.0 g (65.1 mmol) of 4-chlorophenyl isocyanate in 100 ml of dichloromethane is mixed with 400 mg (0.63 mmol) of dibutyltin dilaurate and stirred for 24 hours at room temperature. The reaction mixture is poured into water and extracted with ethyl acetate. The organic phase is evaporated: (R) - (4-chlorophenylcarbamoyloxy) phenylacetic acid as a colorless solid; ESI 306
• 2. 1.2 A solution of 183 mg (0.600 mmol) of (R) - (4-chlorophenylcarbamoyloxy) phenylacetic acid, 129 mg (0.588 mmol) of 1- (4-aminophenyl) piperidin-2-one-O-methyl-oxime, 192 mg (1.00 mmol) of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (DAPECI) and 91.9 mg of 0.600 mmol) of hydroxybenzotriazole hydrate (HOBt) in 1 ml of DMF are mixed with 101 mg (1.00 mmol) of 4-methylmorpholine and added for 24 hours stirred at room temperature. The reaction mixture is poured onto saturated sodium bicarbonate solution and the precipitate formed is filtered off. The precipitate is chromatographed on a silica gel column using petroleum ether / ethyl acetate as the eluent: (R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-methoxyimino-piperidin-1-yl) phenyl ] - 2-phenyl-acetamide ("AA") as a colorless solid; ESI 507.
• 3. 1.3 A solution of 50 mg (0.099 mmol) of (R) - (4-chlorophenyl) - carbamic acid- [4- (2-methoxyimino-piperidin-1-yl) phenylcarbamoyl] phenylmethyl ester in 10 ml of methanol mixed with 0.3 g of water-moist Raney nickel and hydrogenated. The reaction mixture is filtered and the filtrate is evaporated. The residue is chromatographed on a silica gel column using dichloromethane / methanol as the eluent: (R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl ] -2-phenylacetamide as a colorless solid; ESI 477.
• 4. 1.4 30 mg (0.063 mmol) of (R) - (4-chlorophenyl) carbamic acid [4- (2-imino-piperidin-1-yl) phenylcarbamoyl] phenylmethyl ester are dissolved in 0.063 ml of 1N HCl and lyophilized: (R) -2- [N- (4-chlorophenyl) carbamoyloxy] - N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide, hydrochloride (" AB ") as a colorless solid; ESI 477.

• 1. 2.1 Eine Lösung von 10.0 g (66.2 mmol) (R)-alpha-Aminophenylessigsäure in 600 ml 0.25 M wäßriger Natriumhydrogencarbonatlösung wird auf 80°C erhitzt und 20.2 g (132 mmol) 4-Chlorphenylisocyanat zugegeben. Das Reaktionsgemisch wird 1 Stunde bei dieser Temperatur gerührt. Man kühlt im Eisbad ab und filtriert den entstandenen Niederschlag ab. Das Filtrat wird mit 2 N HCl angesäuert und der entstandene Niederschlag abfiltriert: (R)-[3-(4-Chlorphenyl)-ureido]- phenylessigsäure als farbloser Feststoff; ESI 305.
• 2. 2.2 Eine Lösung von 366 mg (1.20 mmol) (R)-[3-(4-Chlorphenyl)- ureido]-phenylessigsäure, 248 mg (1.20 mmol) 1-(4-Amino-2-methylphenyl)-pyrrolidin-2-thion, 249 mg (1.30 mmol) N-(3-Dimethylaminopropyl)- N'-ethylcarbodiimidhydrochlorid (DAPECI) und 184 mg (1.20 mmol) Hydroxybenztriazolhydrat (HOBt) in 1 ml DMF wird mit 152 mg (1.50 mmol) 4-Methylmorpholin versetzt und 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird auf gesättigte Natriumhydrogencarbonatlösung gegeben und der entstandene Niederschlag abfiltriert: (R)- 2-[3-(4-Chlorphenyl)-ureido]-N-[3-methyl-4-(2-thioxo-pyrrolidin-1-yl)- phenyl]-2-phenyl-acetamid als farbloser Feststoff; ESI 493.
• 3. 2.3 Eine Lösung von 380 mg (0.771 mmol) (R)-2-[3-(4-Chlorphenyl)- ureido]-N-[3-methyl-4-(2-thioxo-pyrrolidin-1-yl)-phenyl]-2-phenyl-acetamid in 10 ml Aceton wird mit 78.1 µl (1.25 mmol) Iodmethan versetzt und 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird eingedampft und der Rückstand in tert.-Butylmethylether aufgenommen. Der entstandene Niederschlag wird abfiltriert: (R)-1-(4-{2-[3-(4-Chlorphenyl)-ureido]-2-phenyl-acetylamino}-2-methyl-phenyl)-5-methylsulfanyl- 3,4-dihydro-2H-pyrrolium-iodid als farbloser Feststoff; ESI 507.
• 4. 2.4 Eine Lösung von 469 mg (0.739 mmol) (R)-1-(4-{2-[3-(4- Chlorphenyl)-ureido]-2-phenyl-acetylamino}-2-methyl-phenyl)-5- methylsulfanyl-3,4-dihydro-2H-pyrrolium-iodid in 30 ml Ethanol wird mit 308 mg (4.00 mmol) Ammoniumacetat versetzt und 24 Stunden zum Sieden erhitzt. Das Reaktionsgemisch wird eingedampft und der Rückstand in Wasser aufgenommen. Der entstandene Niederschlag wird abfiltriert: (R)-2-[3-(4-Chlorphenyl)-ureido]-N-[4-(2-imino-pyrrolidin-1-yl)-3- methyl-phenyl]-2-phenyl-acetamid als farbloser Feststoff; ESI 476.
• 5. 2.5 170 mg (0.357 mmol) (R)-2-[3-(4-Chlorphenyl)-ureido]-N-[4-(2- imino-pyrrolidin-1-yl)-3-methyl-phenyl]-2-phenyl-acetamid werden in 2 ml 0.1 N HCl in 2-Propanol gelöst und mit tert.Butylmethylether versetzt. Der entstandene Niederschlag wird abfiltriert: (R)-2-[3-(4-Chlorphenyl)-ureido]- N-[4-(2-imino-pyrrolidin-1-yl)-3-methyl-phenyl]-2-phenyl-acetamid, Hydrochlorid ("BA") als farbloser Feststoff; ESI 476.

The following compounds are obtained analogously
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, hydrochloride, ESI 491;
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-iminopyrrolidin-1-yl) -3-methylphenyl] -2-phenylacetamide, hydrochloride, ESI 477;
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-chlorophenyl) acetamide,
(S) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] propionamide,
(R) -2- [N- (5-chloropyridin-2-yl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-2H-pyridin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (5-chlorothiophen-2-yl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (3-iminomorpholin-4-yl) phenyl] -2-phenyl-acetamide,
2- [N- (4-Chlorophenyl) carbamoyloxy] -N- [4- (2-methoxyimino-piperidin-1-yl) -3-methylphenyl] -2- (2-chlorophenyl) acetamide, ESI 555 ;
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, ESI 521;
(S) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, ESI 521;
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-methoxyiminopyrrolidin-1-yl) phenyl] -2-phenylacetamide, ESI 493;
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2- (2-chlorophenyl) acetamide, ESI 555;
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-azabicyclo [2.2.2] octan-3-imino-2-yl) phenyl] -2-phenyl acetamide. Example 2 Preparation of (R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-piperidin-1-yl) -3-methylphenyl] -2-phenyl- acetamide

• 1. 2.1 A solution of 10.0 g (66.2 mmol) of (R) -alpha-aminophenylacetic acid in 600 ml of 0.25 M aqueous sodium hydrogen carbonate solution is heated to 80 ° C. and 20.2 g (132 mmol) of 4-chlorophenyl isocyanate are added. The reaction mixture is stirred at this temperature for 1 hour. It is cooled in an ice bath and the precipitate formed is filtered off. The filtrate is acidified with 2N HCl and the precipitate formed is filtered off: (R) - [3- (4-chlorophenyl) -ureido] - phenylacetic acid as a colorless solid; ESI 305.
• 2.2.2 A solution of 366 mg (1.20 mmol) of (R) - [3- (4-chlorophenyl) ureido] phenylacetic acid, 248 mg (1.20 mmol) of 1- (4-amino-2-methylphenyl) pyrrolidine 2-thione, 249 mg (1.30 mmol) N- (3-dimethylaminopropyl) - N'-ethylcarbodiimide hydrochloride (DAPECI) and 184 mg (1.20 mmol) hydroxybenzotriazole hydrate (HOBt) in 1 ml DMF is mixed with 152 mg (1.50 mmol) 4- Methylmorpholine added and stirred for 24 hours at room temperature. The reaction mixture is added to saturated sodium bicarbonate solution and the precipitate formed is filtered off: (R) - 2- [3- (4-chlorophenyl) -ureido] -N- [3-methyl-4- (2-thioxo-pyrrolidin-1-yl ) - phenyl] -2-phenyl-acetamide as a colorless solid; ESI 493.
• 3. 2.3 A solution of 380 mg (0.771 mmol) of (R) -2- [3- (4-chlorophenyl) - ureido] -N- [3-methyl-4- (2-thioxo-pyrrolidin-1-yl) -phenyl] -2-phenyl-acetamide in 10 ml acetone is mixed with 78.1 µl (1.25 mmol) iodomethane and stirred for 24 hours at room temperature. The reaction mixture is evaporated and the residue is taken up in tert-butyl methyl ether. The resulting precipitate is filtered off: (R) -1- (4- {2- [3- (4-chlorophenyl) -ureido] -2-phenyl-acetylamino} -2-methyl-phenyl) -5-methylsulfanyl-3, 4-dihydro-2H-pyrrolium iodide as a colorless solid; ESI 507.
• 4. 2.4 A solution of 469 mg (0.739 mmol) of (R) -1- (4- {2- [3- (4-chlorophenyl) -ureido] -2-phenyl-acetylamino} -2-methyl-phenyl) - 5-methylsulfanyl-3,4-dihydro-2H-pyrrolium iodide in 30 ml of ethanol is mixed with 308 mg (4.00 mmol) of ammonium acetate and heated to boiling for 24 hours. The reaction mixture is evaporated and the residue is taken up in water. The resulting precipitate is filtered off: (R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-pyrrolidin-1-yl) -3-methylphenyl] -2- phenyl acetamide as a colorless solid; ESI 476.
• 5. 2.5 170 mg (0.357 mmol) (R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-pyrrolidin-1-yl) -3-methylphenyl] -2-phenyl-acetamide are dissolved in 2 ml 0.1 N HCl in 2-propanol and mixed with tert-butyl methyl ether. The resulting precipitate is filtered off: (R) -2- [3- (4-chlorophenyl) -ureido] - N- [4- (2-imino-pyrrolidin-1-yl) -3-methylphenyl] -2- phenyl acetamide, hydrochloride ("BA") as a colorless solid; ESI 476.

• 1. 3.1 Eine Lösung von 366 mg (1.20 mmol) (R)-[3-(4-Chlorphenyl)- ureido]-phenylessigsäure, 254 mg (1.20 mmol) 1-(4-Amino-phenyl)- pyrrolidin-2-ylidenamin Hydrochlorid, 230 mg (1.20 mmol) N-(3- Dimethylaminopropyl)-N'-ethylcarbodiimidhydrochlorid (DAPECI) und 184 mg (1.20 mmol) Hydroxybenztriazolhydrat (HOBt) in 1 ml DMF wird 24 Stunden bei Raumtemperatur gerührt. Das Reaktionsgemisch wird auf gesättigte Natriumhydrogencarbonatlösung gegeben und der entstandene Niederschlag abfiltriert: (R)-2-[3-(4-Chlorphenyl)-ureido]-N-[4-(2-iminopyrrolidin-1-yl)-phenyl]-2-phenyl-acetamid als farbloser Feststoff; ESI 462.
• 2. 3.2 260 mg (0.563 mmol) (R)-2-[3-(4-Chlorphenyl)-ureido]-N-[4-(2- imino-pyrrolidin-1-yl)-phenyl]-2-phenyl-acetamid werden in 5.6 ml 0.1 N HCl in 2-Propanol gelöst und mit tert.Butylmethylether versetzt. Der entstandene Niederschlag wird abfiltriert: (R)-2-[3-(4-Chlorphenyl)-ureido]- N-[4-(2-imino-pyrrolidin-1-yl)-phenyl]-2-phenyl-acetamid, Hydrochlorid als farbloser Feststoff; ESI 462.

The following compounds are obtained analogously
(R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-piperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, hydrochloride, ESI 490;
(R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(S) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] propionamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] valeric acid amide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [3- (5-chloro-thiophene-2-yl) -ureido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(S) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-methoxyimino-piperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, ESI 520 ;
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-methoxyimino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide, ESI 492. Example 3 Preparation of (R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide

• 1. 3.1 A solution of 366 mg (1.20 mmol) (R) - [3- (4-chlorophenyl) ureido] phenylacetic acid, 254 mg (1.20 mmol) 1- (4-aminophenyl) pyrrolidin-2- ylidenamine hydrochloride, 230 mg (1.20 mmol) N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (DAPECI) and 184 mg (1.20 mmol) hydroxybenzotriazole hydrate (HOBt) in 1 ml DMF is stirred for 24 hours at room temperature. The reaction mixture is poured onto saturated sodium bicarbonate solution and the precipitate formed is filtered off: (R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-iminopyrrolidin-1-yl) -phenyl] -2 -phenyl acetamide as a colorless solid; ESI 462.
• 2. 3.2 260 mg (0.563 mmol) of (R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-pyrrolidin-1-yl) -phenyl] -2-phenyl -acetamide are dissolved in 5.6 ml 0.1 N HCl in 2-propanol and mixed with tert-butyl methyl ether. The resulting precipitate is filtered off: (R) -2- [3- (4-chlorophenyl) -ureido] - N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide, Hydrochloride as a colorless solid; ESI 462.

The connection is obtained analogously
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-thienyl acetamide, hydrochloride, ESI 468. Pharmacological Data affinity for receptors Table 1

The following examples relate to pharmaceutical preparations:

Example A injection Vials

A solution of 100 g of an active ingredient of formula I and 5 g Disodium hydrogen phosphate is dissolved in 3 l of double-distilled water with 2 n Hydrochloric acid adjusted to pH 6.5, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. each Injection glass contains 5 mg of active ingredient.

Example B suppositories

A mixture of 20 g of an active ingredient of the formula I is melted with 100 g soy lecithin and 1400 g cocoa butter, pour into molds and leave cool. Each suppository contains 20 mg of active ingredient.

Example C solution

A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH ₂ PO ₄ .2H ₂ O, 28.48 g of Na ₂ HPO ₄ . 12H ₂ O and 0.1 g benzalkonium chloride in 940 ml double-distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

Example D ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.

Example E tablets

A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg Potato starch, 0.2 kg talc and 0.1 kg magnesium stearate is more common Formed into tablets in such a way that each tablet contains 10 mg of active ingredient contains.

Example F dragees

Analogously to Example E, tablets are pressed, which are then made in the usual manner Wise with a coating of sucrose, potato starch, talc, tragacanth and dye are coated.

Example 6 capsules

2 kg of active ingredient of the formula I are in the usual way Hard gelatin capsules filled so that each capsule contains 20 mg of the active ingredient.

Example H ampoules

A solution of 1 kg of active ingredient of formula I in 60 l of double distilled Water is filtered sterile, filled into ampoules, under sterile Conditions lyophilized and sealed sterile. Each ampoule contains 10 mg Active ingredient.

Claims (26)

1. Compounds of formula I.


wherein
D phenyl, pyridyl or thienyl which is unsubstituted or mono- or polysubstituted by Hal, A, OR ² , N (R ² ) ₂ , NO ₂ , CN, COOR ² or CON (R ² ) ₂ ,
X NR ³ or O,
R ¹ H, Ar, Het, cycloalkyl or
A, which may be substituted by OR ² , SR ² , N (R ² ) ₂ , Ar, Het, cycloalkyl, CN, COOR ² or CON (R ² ) ₂ ,
R ² H, A, - [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het, - [C (R ³ ) ₂ ] _n -cycloalkyl, - [C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
R ³ H or A,
W - [C (R ³ ) ₂ ] _n -,
Y alkylene, cycloalkylene, het-diyl or ar-diyl,
T is a mononuclear or dinuclear saturated, unsaturated or aromatic carbo- or heterocycle with 1 to 4 N, O and / or S atoms, which is mono- or doubly represented by = S, = NR ² , = NOR ² , = NCOR ² , = NCOOR ² , = NOCOR and is further substituted one, two or three times by Hal, A, - [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het, - [C (R ³ ) ₂ ] _n -cycloalkyl, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ² , CON (R ² ) ₂ , NR ² COA, NR ² CON (R ² ) ₂ , NR ² SO ₂ A, COR ² , SO ₂ NR ² and / or S (O) _m A can be substituted,
A unbranched or branched alkyl having 1-10 C atoms, in which one or two CH ₂ groups by O or S atoms and / or by -CH = CH groups and / or 1-7 H atoms by F can be replaced
Ar unsubstituted or single, double or triple by Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ , CON (R ³ ) ₂ , NR ³ COA, NR ³ CON (R ³ ) ₂ , NR ³ SO ₂ A, COR ³ , SO ₂ N (R ³ ) ₂ , S (O) _m A, - [C (R ³ ) ₂ ] _n -COOR ^{2 '} or -O- [C (R ³ ) ₂ ] _o -COOR ^{2 '} substituted phenyl, naphthyl or biphenyl,
R ^{2 '} H, A, - [C (R ³ ) ₂ ] _n -Ar', - [C (R ³ ) ₂ ] _n -Het ', - [C (R ³ ) ₂ ] _n -cycloalkyl, - [ C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
H ^{2 ''} H, A, - [C (R ³ ) ₂ ] _n -Ar 'or - [C (R ³ ) ₂ ] _n -cycloalkyl, - [C (R ³ ) ₂ ] _n -N (R ³ ) ₂ or - [C (R ³ ) ₂ ] _n -OR ³ ,
Ar 'phenyl or benzyl which is unsubstituted or mono- or disubstituted by Hal or A,
Het a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, = S, = N (R ³ ) ₂ , Hal, A, - [C (R ³ ) ₂ ] _n -Ar, - [C (R ³ ) ₂ ] _n -Het ¹ , - [C (R ³ ) ₂ ] _n -Cycoalkyl, - [C ( R ³ ) ₂ ] _n -OR ^{2 '} , - [C (R ³ ) ₂ ] _n -N (R ^2' ) ₂ , NO ₂ , CN, - [C (R ³ ) ₂ ] _n -COOR ^{2 '} , - [C (R ³ ) ₂ ] _n -CON (R ^{2 '} ) ₂ , - [C (R ³ ) ₂ ] _n -NR ^2' COA, NR ^{2 '} CON (R ^2' ) ₂ , - [C ( R ³ ) ₂ ] _n -NR ^{2 '} SO ₂ A, COR ^2' , SO ₂ NR ^{2 '} and / or S (O) _m A can be substituted,
Het ^{1 is} a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 2 N, O and / or S atoms, which is unsubstituted or mono- or disubstituted by carbonyl oxygen, = S, = N (R ³ ) ₂ , Hal, A, OR ^{2 "} , N (R ^2" ) ₂ , NO ₂ , CN, COOR ^{2 "} , CON (R ^2" ) ₂ , NR ^{2 "} COA, NR ^2" CON (R ^{2 ″} ) ₂ , NR ^{2 ″} SO ₂ A, COR ^{2 ″} , SO ₂ NR ^{2 ″} and / or S (O) _m A can be substituted,
Hal F, Cl, Br or I,
n 0, 1 or 2,
m 0, 1 or 2,
o, 1, 2 or 3
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 2. Compounds according to claim 1, wherein
D unsubstituted or mono- or disubstituted by Hal, A, OR ² or COOR ² , or unsubstituted or monosubstituted by Hal pyridyl or thienyl
means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 3. Compounds according to one or more of claims 1-2, wherein
R ² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 4. Compounds according to one or more of claims 1-3, wherein
R ¹ H, unsubstituted or monosubstituted phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl,
means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 5. Compounds according to one or more of claims 1-4, wherein
X is NH or O,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 6. Compounds according to one or more of claims 1-5, wherein
W (CH ₂ ) _n means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 7. Compounds according to one or more of claims 1-6, wherein
Y means Ar-diyl or Het-diyl,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 8. Compounds according to one or more of claims 1-7, wherein
T is a mononuclear or dinuclear saturated, unsaturated or aromatic carbocycle or heterocycle with 1 to 2 N and / or O atoms, which is mono- or doubly represented by = S, = NR ² , = NOR ² , = NCOR ² , = NCOOR ² , = NOCOR ^{2 is} substituted and can also be substituted once or twice by Hal or A,
means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 9. Compounds according to one or more of claims 1-8, wherein
T denotes a mono- or dinuclear saturated or unsaturated heterocycle with 1 to 2 N and / or O atoms, which is mono- or disubstituted by = NR ² , = S or = NOR ² ,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 10. Compounds according to one or more of claims 1-9, wherein
T mono- or doubly substituted by = NR ² , = S or = NOR ² piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1 , 3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl
means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 11. Compounds according to one or more of claims 1-10, wherein
T mono- or doubly substituted by = NR ^2b , = S or = NOR ^2b piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1 , 3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA ',
A 'alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1-7 H atoms can be replaced by F,
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 12. Compounds according to one or more of claims 1-11, wherein
T mono- or doubly substituted by = NR ^2b , = S or = NOR ^2b piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1 , 3-oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl,
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 13. Compounds according to one or more of claims 1-12, wherein
Ar is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO ₂ A, COOR ² , SO ₂ NH ₂ or CN,
means
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 14. Compounds according to one or more of claims 1-13, wherein
D unsubstituted or simply substituted by Hal phenyl or unsubstituted or simply substituted by Hal pyridyl or thienyl,
R ¹ H, unsubstituted or monosubstituted phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl,
X NH or O,
W is missing,
Y ar-diyl, pyridine-diyl or piperidine-diyl,
Ar is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO ₂ A, COOR ² , SO ₂ NH ₂ or CN,
T simply piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- substituted by = NR ^2b , = S or = NOR ^2b Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 15. Compounds according to one or more of claims 1-14, wherein
D unsubstituted or simply substituted by Hal phenyl or unsubstituted or simply substituted by Hal pyridyl or thienyl,
R ¹ H, unsubstituted or monosubstituted phenyl or alkyl having 1-6 C atoms, which can be substituted by thiophene, imidazole, indole, SR ² , cycloalkyl or phenyl,
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- substituted by = NR ^2b , = S or = NOR ^2b Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 16. Compounds according to one or more of claims 1-15, wherein
D unsubstituted or simply substituted by Hal phenyl or thienyl,
R ¹ H, unsubstituted or simply substituted by Hal, phenyl or alkyl having 1-6 C atoms,
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- substituted by = NR ^2b , = S or = NOR ^2b Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 17. Compounds according to one or more of claims 1-16, wherein
D unsubstituted or simply substituted by Hal phenyl or thienyl,
R ¹ H, phenyl which is unsubstituted or simply substituted by Hal, alkyl having 1-6 C atoms or Het ',
X NH or O,
W is missing,
Y ar-diyl,
Ar is phenyl which is unsubstituted or substituted once or twice by Hal or A,
T simply piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3- substituted by = NR ^2b , = S or = NOR ^2b Oxazolidin-3-yl, 2H-pyridazin-2-yl, azepan-1-yl, 2-aza-bicyclo [2.2.2] octan-2-yl,
R ^2b H, OH or OA '',
A '' methyl, ethyl, propyl, isopropyl or butyl,
Het '2-thienyl or 2-furyl,
mean,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 18. Compounds according to claim 1 selected from the group
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-methoxyimino-piperidin-1-yl) phenyl] -2-phenylacetamide,
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-iminopiperidine-1-yl) phenyl] -2-phenylacetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) -3-methylphenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-pyrrolidin-1-yl) -3-methylphenyl] -2-phenylacetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-chlorophenyl) acetamide,
(S) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] propionamide,
(R) -2- [N- (5-chloro-pyridin-2-yl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (2-imino-2H-pyridin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (5-chlorothiophen-2-yl) carbamoyloxy] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [N- (4-chlorophenyl) carbamoyloxy] -N- [4- (3-iminomorpholin-4-yl) phenyl] -2-phenyl-acetamide,
2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2- (2-chlorophenyl) acetamide,
(R) -2- [N- (4-chlorophenyl) -carbamoyloxyl] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2-phenylacetamide,
(S) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2-phenylacetamide,
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2--methoxyimino-pyrrolidin-1-yl) phenyl] -2-phenylacetamide,
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2- (2-chlorophenyl) acetamide,
(R) -2- [N- (4-chlorophenyl) -carbamoyloxy] -N- [4- (2-azabicyclo [2.2.2] octan-3-imino-2-yl) phenyl] -2-phenyl -acetamide
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) -3-methylphenyl] -2-phenylacetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) -3-methylphenyl] -2-phenylacetamide, hydrochloride,
(R) -2- [3- (4-chlorophenyl) -ureido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(S) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] propionamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2-phenyl-acetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-piperidin-1-yl) phenyl] valeric acid amide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-imino-pyrrolidin-1-yl) phenyl] -2- (2-fluorophenyl) acetamide,
(R) -2- [3- (5-chloro-thiophene-2-yl) -ureido] -N- [4- (2-imino-piperidin-1-yl) phenyl] -2-phenyl-acetamide,
(S) -2- [3- (4-chlorophenyl) ureido] -N- [4- (2-methoxyiminopiperidin-1-yl) -3-methyl-phenyl] -2-phenylacetamide,
(R) -2- [3- (4-chlorophenyl) ureido] -N- [4- (2--methoxyimino-pyrrolidin-1-yl) phenyl] -2-phenylacetamide,
(R) -2- [3- (4-chlorophenyl) urido] -N- [4- (2-iminopyrrolidin-1-yl) phenyl] -2-thienyl acetamide,
as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios. 19. A process for the preparation of compounds of formula I according to claims 1-17 and their pharmaceutically usable derivatives, solvates and stereoisomers, characterized in that 1. a compound of formula II


wherein
R ¹ , W, Y and T have the meaning given in claim 1,
with a compound of formula III

DN = C = O III

wherein
D has the meaning given in claim 1,
implements,
or 2. a compound of formula IV

H ₂ NWYT IV

wherein W, Y and T have the meaning given in claim 1,
with a compound of formula V


wherein
L means Cl, Br, I or a free or reactively functionally modified OH group and
R ¹ , X and D have the meanings given in Claim 1,
or 3. and / or in a compound of formula I converting a radical T into another radical T,
for example by 4. converts a sulfanyl compound into an imino compound, and or
converts a base or acid of the formula I into one of its salts. 20. Compounds of formula I according to one or more of the Claims 1 to 18 as inhibitors of the coagulation factor Xa. 21. Compounds of formula I according to one or more of the Claims 1 to 18 as inhibitors of coagulation factor VIIa. 22. Medicament containing at least one compound of the formula I. according to one or more of claims 1 to 18 and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all proportions, as well optionally carriers and / or auxiliaries. 23. Medicament containing at least one compound of the formula I. according to one or more of claims 1 to 18 and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all proportions, and at least one other active pharmaceutical ingredient. 24. Use of compounds according to one or more of the Claims 1 to 18 and / or their physiologically acceptable Salts and solvates for the manufacture of a medicament for Treatment of thrombosis, myocardial infarction, arteriosclerosis, Inflammation, apoplexy, angina pectoris, restenosis after Angioplasty, intermittent claudication, migraines, tumors, Tumor diseases and / or tumor metastases. 25. Set, consisting of separate packs of 1. an effective amount of a compound of formula I according to one or more of claims 1 to 18 and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios,
and 2. an effective amount of another drug ingredient. 26. Use of compounds of the formula I according to one or more of claims 1 to 18 and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios,
for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases,
in combination with at least one other active pharmaceutical ingredient.